Mumbai-based Lupin gets FDA warning for two manufacturing sites; Ionis promotes inotersen head as new COO
→ Indian drug manufacturer Lupin received a warning letter from the FDA claiming that it had violated good manufacturing practices, the company disclosed in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.